ClinicalTrials.gg
CompletedNCT02501096Updated Jul 20, 2023Results posted

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

A Phase 1/2 interventional study of Lenvatinib and Pembrolizumab in Tumors, sponsored by Eisai Inc.. Completed at 64 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
357
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).

02

Conditions studied

  • Tumors

Browse trials for

Keywords

  • Lenvatinib
  • Lenvima
  • E7080
  • Phase 1b/2
  • Pembrolizumab
  • Keytruda
  • Solid tumors
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 357 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Phase 1b: and/or cytologically confirmed selected solid tumor types that have progressed after treatment with approved therapies or for which there are no standard effective therapies available. If nivolumab or pembrolizumab is an approved therapy for the participant's tumor type, but the participant has not been treated with it, the Investigator may enroll the participant in this study.

    Phase 2: Histologically and/or cytologically confirmed metastatic selected solid tumor types with 0-2 . If previously treated, participant has progressed after previous treatment. For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-programmed cell death protein 1 (), anti-PD-1 ligand 1 (anti-PD-L1), or anti-PD-1 ligand 2 (anti-PD-L2) agent. For the renal cell carcinoma (RCC) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies, the regimen with an anti-PD-1/PD-L1 mAb must be the most recent therapy. Selected tumor types of both phases: NSCLC, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal melanoma)

  2. of 12 weeks or more
  3. Phase 2: meeting the following criteria:

    1. At least 1 lesion of greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node that is serially measurable according to irRECIST (immune-related ) using computerized tomography/magnetic resonance imaging (CT/MRI)
    2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show subsequent evidence of substantial size increase to be deemed a target lesion
  4. Participants must have an (ECOG) Performance Status of 0 to 1
  5. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1
  6. Adequate renal function defined as creatinine less than or equal to 1.5* (upper limit of normal) or calculated greater than or equal to 40 mL/min per the Cockcroft and Gault formula with creatinine levels greater than 1.5*ULN
  7. Adequate bone marrow function:

    1. (ANC) greater than or equal to 1500/mm3 (greater than or equal to 1.5 X 103/uL)
    2. greater than or equal to 100,000/mm3 (greater than or equal to 100 X 109/L)
    3. greater than or equal to 9.0 g/dL
  8. Adequate blood coagulation function as evidenced by an (INR) less than or equal to 1.5
  9. Adequate liver function as evidenced by less than or equal to 1.5 times the ULN and alkaline phosphatase (ALP), (ALT), and aspartate aminotransferase (AST) less than or equal to 3*ULN (in the case of liver metastases less than or equal to 5*ULN). In case ALP is greater than 3 X ULN (in the absence of liver metastases) or greater than 5 X ULN (in the presence of liver metastases) AND the participant also is known to have bone metastases, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP
  10. Males or females age greater than or equal to 18 years at the time of
  11. Participants with known will be eligible if they have completed the primary brain therapy (such as whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection) and if they have remained clinically stable, asymptomatic and off of for at least 28 days before starting study treatment.
  12. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [β-hCG]) at the Screening Visit and the Baseline Visit. A pregnancy test needs to be performed within 72 hours of the first dose of study drug. Females of must agree to use a highly effective method of for the entire study period and for 120 days after study discontinuation, ie

    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device (IUD) or hormone-releasing system (IUS)
    • a contraceptive implant
    • an oral contraceptive** (with additional barrier method) OR
    • have a vasectomized partner with confirmed azoospermia.

    NOTES:

    • All females will be considered to be of childbearing potential unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
    • Must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the study
  13. Male participants who are partners of women of childbearing potential must use a condom + spermicide and their female partners if of childbearing potential must use a highly effective method of contraception (see methods described in Inclusion Criterion #12) beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 120 days after the last dose of study drug, unless the male participants are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile.
  14. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol
  15. or a newly obtained biopsy must be available prior to the first dose of study drug for biomarker analysis. In the case archival tissue cannot be provided, participants with inaccessible tumors for biopsy specimens can be enrolled without a biopsy upon consultation and agreement by the sponsor Note: In case of submitting unstained cut slides, freshly cut slides should be submitted to the testing laboratory within 14 days from when the slides are cut.

Exclusion criteria

Exclusion Criteria:

  1. Prior anticancer treatment within 28 days (or 5 times the half-life time, whichever is shorter) or any agent within 30 days prior to the first dose of study drugs. All acute toxicities related to prior treatments must be resolved to Grade less than or equal to 1
  2. Participants must have recovered adequately from any toxicity and/or complications from major surgery prior to starting therapy
  3. Participants having greater than 1+ proteinuria on urinalysis will undergo 24-h urine collection for quantitative assessment of proteinuria. Participants with urine protein greater than or equal to 1 g/24-hour will be ineligible.
  4. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
  5. congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months
  6. Prolongation of (QTc) interval to greater than 480 msec
  7. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
  8. Active infection (any infection requiring systemic treatment)
  9. Participant is known to be positive for (HIV), , or
  10. Serious nonhealing wound, ulcer, or bone fracture
  11. Known intolerance to either of the study drugs (or any of the )
  12. History of organ allograft (Participant has had an allogenic tissue/solid organ transplant)
  13. Biologic response modifiers (eg, granulocyte colony-stimulating factor) within 4 weeks before study entry. Chronic erythropoietin therapy is permitted provided that no dose adjustments were made within 2 months before first dose of study treatment
  14. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial
  15. Females who are pregnant or breastfeeding
  16. Excluding the primary tumor leading to enrollment in this study, any other active (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past 24 months
  17. Prior treatment with lenvatinib or any , anti-PD-L1, or anti-PD-L2 agent, excluding melanoma and NSCLC where prior treatment with one PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed, and excluding RCC where prior treatment with one regimen containing an anti-PD-1/PD-L1 mAb is required.
  18. Has a diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study treatment. The use of physiologic doses of corticosteroids (up to 7.5mg/d of prednisone or equivalent) may be approved after consultation with the sponsor.
  19. No active disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  20. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
  21. Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
357 participants (actual)

Study arms

  • Experimental
    Lenvatinib + Pembrolizumab

    Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma.

    Drug: Lenvatinib · Drug: Pembrolizumab

Interventions

  • Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.

    Also known as: Lenvima, E7080

  • Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.

    Also known as: Keytruda, MK-3475

06

What researchers measure

Primary outcomes

  1. Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib

    MTD was confirmed if no more than 3 participants experience dose-limiting toxicities(DLTs)during first 3 weeks (Cycle 1) of treatment.If MTD was not confirmed at dose level,then enrollment was proceeded to next lower dose level.Sponsor and investigators reviewed all participants' safety;clinical data to jointly determine RP2D of combination of treatment.DLT may be any of following: hematological/nonhematological toxicities considered to be at least possibly related to Lenvatinib/pembrolizumab occurring during Cycle 1;Failure to administer greater than or equal to (\>=) 75 percent (%) of planned dosage of lenvatinib as result of treatment-related toxicity during Cycle 1;Who discontinue treatment due to treatment-related toxicity.Greater than 2 week delay in starting Cycle 2 because of treatment-related toxicity,even if toxicity does not meet DLT criteria.Toxicity was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03(NCI CTCAE v 4.03).

    Time frame: Cycle 1 (21 days)

  2. Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib

    A DLT was defined as any of the following: any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1. Failure to administer \>=75% of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1. Participants who discontinue treatment due to treatment-related toxicity. Greater than 2 week delay in starting Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria. Toxicity was evaluated as per NCI CTCAE v 4.03.

    Time frame: Cycle 1 (21 days)

  3. Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24

    ORR was defined as the percentage of participants whose best overall response (BOR) was immune related complete response (irCR) or immune related partial response (irPR) based on investigator assessment according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Week 24

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    TEAE: adverse event (AE) emerged during treatment, having been absent at pretreatment or reemerged during treatment, present at pretreatment but stopped before treatment or worsened in severity during treatment relative to pretreatment state, when AE is continuous. AE: any untoward medical occurrence in participant administered an investigational product. TEAEs were based on participants laboratory tests, regular measurement of vital signs, echocardiograms/multigated acquisition scans to assess left ventricular ejection fraction and electrocardiograms parameter values. TESAE: any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; a congenital anomaly/birth defect or was medically important due to reasons other than above criteria.

    Time frame: From date of first dose up to 30 days after the last dose of study drugs (Up to 74 months)

  2. Objective Response Rate (ORR) Based on irRECIST Version 1.1

    ORR was defined as the percentage of participants whose BOR was irCR or irPR according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: From date of first dose of study drug administration until immune related (irPD), development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)

  3. Progression-free Survival (PFS) Based on irRECIST Version 1.1

    PFS was defined as the time from the first dose date to the date of irPD or date of death (whichever occurred first) according to irRECIST version 1.1. irPD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression).

    Time frame: From date of first dose of study drug administration to date of irPD or date of death, whichever occurred first (up to 73 months)

  4. Overall Survival (OS)

    OS was defined as the time from the first dose date to the date of death from any cause.

    Time frame: From the first dose until death from any cause, up to 73 months

  5. Disease Control Rate (DCR) Based on irRECIST Version 1.1

    DCR: percentage of participants with a confirmed irCR, irPR, or ir-stable disease (SD) (duration of irSD greater than or equal to \[\>=\] 5 weeks). DCR was assessed on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).

    Time frame: From first dose of the study drug until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)

  6. Clinical Benefit Rate (CBR) Based on irRECIST Version 1.1

    CBR was defined as the percentage of participants with BOR of irCR or irPR or irdurable stable disease (irdSD) (duration of irSD \>=23 weeks) \[irCR + irPR + irdSD\] based on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).

    Time frame: From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)

  7. Durable Stable Disease Rate (DSDR) Based on irRECIST Version 1.1

    Durable SD rate is defined as the percentage of participants whose observed BOR is irSD and the duration of irSD is \>=23 weeks based on irRECIST v1.1.

    Time frame: From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)

  8. Duration of Objective Response (DOR) Based on irRECIST Version 1.1

    DOR: time from date of first observation of response (irPR or irCR) to date of the first observation of progression based on irRECIST 1.1, or date of death, whatever the cause. irCR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have reduction in their short axis \<10 mm. irPR: at least 30% decrease in sum of diameter (SOD) of target lesions, taking as reference baseline sum diameters. irPD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in SOD of target lesions, taking as reference smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

    Time frame: First documentation of irCR or irPR until first documentation of progression or death (up to 73 months)

  9. Phase 1b: Plasma Concentrations of Lenvatinib

    Observed plasma concentration of Lenvatinib was reported here quantified by liquid chromatography with tandem mass spectrometry (LCMS/MS) method.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days)

  10. Plasma Concentrations of Lenvatinib

    Observed plasma concentration of Lenvatinib was reported here quantified by LCMS/MS method.

    Time frame: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days):

07

Results

Posted Jul 20, 2023

Participant flow

Participants took part in the study at 62 investigative sites in the United States, Spain and Norway from 22 July 2015 to 11 July 2022.

Participant flow — Overall Study
MilestonePhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Started21124145212122201
Phase 1b participants who received, lenvatinib 20 mg/day + pembrolizumab 200 mg.002611000
Phase 2 participants who received, lenvatinib 20 mg/day + pembrolizumab 200 mg00122139202022201
Completed000000000
Not completed21124145212122201
Withdrew: Lost to follow-up000011300
Withdrew: Withdrawal by subject1071322230
Withdrew: Survival follow-up discontinued by sponsor00295832210
Withdrew: Death118874151615161

Outcome measures

PrimaryPhase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib

MTD was confirmed if no more than 3 participants experience dose-limiting toxicities(DLTs)during first 3 weeks (Cycle 1) of treatment.If MTD was not confirmed at dose level,then enrollment was proceeded to next lower dose level.Sponsor and investigators reviewed all participants' safety;clinical data to jointly determine RP2D of combination of treatment.DLT may be any of following: hematological/nonhematological toxicities considered to be at least possibly related to Lenvatinib/pembrolizumab occurring during Cycle 1;Failure to administer greater than or equal to (\>=) 75 percent (%) of planned dosage of lenvatinib as result of treatment-related toxicity during Cycle 1;Who discontinue treatment due to treatment-related toxicity.Greater than 2 week delay in starting Cycle 2 because of treatment-related toxicity,even if toxicity does not meet DLT criteria.Toxicity was evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03(NCI CTCAE v 4.03).

Time frame:
Cycle 1 (21 days)
Reported as:
Number · milligram (mg)
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib
milligram (mg)Phase 1b: All Participants
MTD20
RP2D20
PrimaryPhase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib

A DLT was defined as any of the following: any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1. Failure to administer \>=75% of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1. Participants who discontinue treatment due to treatment-related toxicity. Greater than 2 week delay in starting Cycle 2 because of a treatment-related toxicity, even if the toxicity does not meet DLT criteria. Toxicity was evaluated as per NCI CTCAE v 4.03.

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib
ParticipantsPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: ECPhase 1b, Lenvatinib 20 mg/Day + Pembrolizumab 200 mg: Melanoma
Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) of Lenvatinib110000
PrimaryObjective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24

ORR was defined as the percentage of participants whose best overall response (BOR) was immune related complete response (irCR) or immune related partial response (irPR) based on investigator assessment according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 24
percentage of participantsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Objective Response Rate (ORR) Based on Immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) Version 1.1 at Week 2439.5 (30.9 to 48.7)56.6 (48.1 to 64.8)47.6 (25.7 to 70.2)23.8 (8.2 to 47.2)31.8 (13.9 to 54.9)25.0 (8.7 to 49.1)0 (NA to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

TEAE: adverse event (AE) emerged during treatment, having been absent at pretreatment or reemerged during treatment, present at pretreatment but stopped before treatment or worsened in severity during treatment relative to pretreatment state, when AE is continuous. AE: any untoward medical occurrence in participant administered an investigational product. TEAEs were based on participants laboratory tests, regular measurement of vital signs, echocardiograms/multigated acquisition scans to assess left ventricular ejection fraction and electrocardiograms parameter values. TESAE: any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; a congenital anomaly/birth defect or was medically important due to reasons other than above criteria.

Time frame:
From date of first dose up to 30 days after the last dose of study drugs (Up to 74 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
TEAEs21124145212122201
TESAEs117381121512170
SecondaryObjective Response Rate (ORR) Based on irRECIST Version 1.1

ORR was defined as the percentage of participants whose BOR was irCR or irPR according to irRECIST version 1.1. irCR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. irPR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
From date of first dose of study drug administration until immune related (irPD), development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Based on irRECIST Version 1.1
percentage of participantsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Objective Response Rate (ORR) Based on irRECIST Version 1.140.3 (31.6 to 49.5)63.4 (55.1 to 71.3)47.6 (25.7 to 70.2)23.8 (8.2 to 47.2)40.9 (20.7 to 63.6)25.0 (8.7 to 49.1)NA (NA to NA)
SecondaryProgression-free Survival (PFS) Based on irRECIST Version 1.1

PFS was defined as the time from the first dose date to the date of irPD or date of death (whichever occurred first) according to irRECIST version 1.1. irPD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions was also considered progression).

Time frame:
From date of first dose of study drug administration to date of irPD or date of death, whichever occurred first (up to 73 months)
Reported as:
Median · months
Progression-free Survival (PFS) Based on irRECIST Version 1.1
monthsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Progression-free Survival (PFS) Based on irRECIST Version 1.17.5 (5.3 to 9.7)14.1 (11.6 to 18.4)5.5 (2.6 to 15.8)5.4 (2.3 to 7.4)4.4 (4.0 to 9.8)5.4 (1.3 to 42.3)1.35 (NA to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the first dose date to the date of death from any cause.

Time frame:
From the first dose until death from any cause, up to 73 months
Reported as:
Median · months
Overall Survival (OS)
monthsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Overall Survival (OS)19.9 (16.2 to 25.9)32.2 (29.8 to 55.8)25.4 (8.6 to 39.5)11.4 (3.6 to 23.3)16.2 (8.6 to 31.8)6.1 (2.4 to 30.1)16.56 (NA to NA)
SecondaryDisease Control Rate (DCR) Based on irRECIST Version 1.1

DCR: percentage of participants with a confirmed irCR, irPR, or ir-stable disease (SD) (duration of irSD greater than or equal to \[\>=\] 5 weeks). DCR was assessed on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).

Time frame:
From first dose of the study drug until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) Based on irRECIST Version 1.1
percentage of participantsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Disease Control Rate (DCR) Based on irRECIST Version 1.184.7 (77.1 to 90.5)93.8 (88.5 to 97.1)81.0 (58.1 to 94.6)76.2 (52.8 to 91.8)90.9 (70.8 to 98.9)70.0 (45.7 to 88.1)NA (NA to NA)
SecondaryClinical Benefit Rate (CBR) Based on irRECIST Version 1.1

CBR was defined as the percentage of participants with BOR of irCR or irPR or irdurable stable disease (irdSD) (duration of irSD \>=23 weeks) \[irCR + irPR + irdSD\] based on irRECIST v1.1. irCR: disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in their short axis to \<10 mm. irPR: at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference baseline sum of longest diameter. irSD: neither sufficient shrinkage to qualify for irPR nor sufficient increase to qualify for irPD, taking as reference smallest sum diameters while on study. irPD: at least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study (this includes baseline sum if that is the smallest on study).

Time frame:
From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR) Based on irRECIST Version 1.1
percentage of participantsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Clinical Benefit Rate (CBR) Based on irRECIST Version 1.158.9 (49.7 to 67.6)80.0 (72.6 to 86.2)61.9 (38.4 to 81.9)57.1 (34.0 to 78.2)45.5 (24.4 to 67.8)40.0 (19.1 to 63.9)NA (NA to NA)
SecondaryDurable Stable Disease Rate (DSDR) Based on irRECIST Version 1.1

Durable SD rate is defined as the percentage of participants whose observed BOR is irSD and the duration of irSD is \>=23 weeks based on irRECIST v1.1.

Time frame:
From first dose date until irPD, development of unacceptable toxicity, participant choice, withdrawal of consent, lost to follow up or discontinuation of this study by the sponsor (up to 73 months)

No measurements were reported for this outcome.

SecondaryDuration of Objective Response (DOR) Based on irRECIST Version 1.1

DOR: time from date of first observation of response (irPR or irCR) to date of the first observation of progression based on irRECIST 1.1, or date of death, whatever the cause. irCR: disappearance of all target and non-target lesions. All pathological (whether target or non-target) must have reduction in their short axis \<10 mm. irPR: at least 30% decrease in sum of diameter (SOD) of target lesions, taking as reference baseline sum diameters. irPD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in SOD of target lesions, taking as reference smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.

Time frame:
First documentation of irCR or irPR until first documentation of progression or death (up to 73 months)
Reported as:
Median · months
Duration of Objective Response (DOR) Based on irRECIST Version 1.1
monthsPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Duration of Objective Response (DOR) Based on irRECIST Version 1.1NA (8.5 to NA)16.6 (9.7 to 18.4)12.5 (2.7 to 28.6)14.5 (2.4 to NA)7.1 (2.2 to 16.8)41.0 (4.6 to NA)—
SecondaryPhase 1b: Plasma Concentrations of Lenvatinib

Observed plasma concentration of Lenvatinib was reported here quantified by liquid chromatography with tandem mass spectrometry (LCMS/MS) method.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days)
Reported as:
Mean · microgram per liter (mcg/L)
Phase 1b: Plasma Concentrations of Lenvatinib
microgram per liter (mcg/L)Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC
Cycle 1 Day 1: 0.5-4 hour102.5 ± 136.44198.0 ± NA
Cycle 1 Day 1: 6-10 hour210.5 ± 65.76—
Cycle 1 Day 15: Predose53.9 ± NA1.8 ± NA
Cycle 1 Day 15: 0.5-4 hour78.4 ± NA2.6 ± NA
Cycle 1 Day 15: 6-10 hour366.0 ± NA424.0 ± NA
Cycle 2 Day 1: Predose35.4 ± 13.08364.0 ± NA
Cycle 2 Day 1: 2-12 hour491.0 ± 247.49374.0 ± NA
Cycle 3 Day 1: Predose23.3 ± 31.92118.0 ± NA
Cycle 4 Day 1: Predose28.0 ± 13.93176.0 ± NA
Cycle 5 Day 1: Predose19.9 ± 14.912.5 ± NA
Cycle 6 Day 1: Predose44.4 ± 42.64210.0 ± NA
SecondaryPlasma Concentrations of Lenvatinib

Observed plasma concentration of Lenvatinib was reported here quantified by LCMS/MS method.

Time frame:
Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post dose; Cycle 1 Day 15: predose, 0.5-4 hours and 6-10 hours post dose, Cycle 2 Day 1: predose, 2-12 hour postdose and Cycles 3,4,5,6 Day 1 predose (Cycle length =21 days):
Reported as:
Mean · mcg/L
Plasma Concentrations of Lenvatinib
mcg/LPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
Cycle 1 Day 1:0.5-4 hour82.2 ± 145.4435.5 ± 78.1324.0 ± 33.5979.9 ± 118.9441.8 ± 100.34123.8 ± 169.05—
Cycle 1 Day 1:6-10 hour231.7 ± 109.67190.8 ± 96.25154.3 ± 69.56224.1 ± 109.95169.7 ± 95.78214.2 ± 86.51116 ± NA
Cycle 1 Day 15:Predose66.6 ± 36.5667.2 ± 80.7052.1 ± 61.7062.9 ± 87.3660.9 ± 46.3861.1 ± 69.5452.2 ± NA
Cycle 1 Day 15:0.5-4 hour129.3 ± 109.72122.4 ± 114.6293.1 ± 117.35275.3 ± 305.30142.8 ± 149.90153.9 ± 135.7945.9 ± NA
Cycle 1 Day 15:6-10 hour271.3 ± 103.60206.3 ± 97.29241.8 ± 241.52266.8 ± 146.41210.6 ± 78.37249.7 ± 91.65161 ± NA
Cycle 2 Day 1:Predose57.2 ± 60.5854.6 ± 64.4349.2 ± 46.6351.6 ± 66.7242.0 ± 48.1622.3 ± 21.6126.1 ± NA
Cycle 2 Day 1:2-12 hour199.7 ± 155.08171.7 ± 119.34218.6 ± 83.83295.0 ± 190.80166.5 ± 128.95204.7 ± 174.60—
Cycle 3 Day 1:Predose53.2 ± 59.5359.0 ± 67.5862.8 ± 65.7799.4 ± 132.3343.7 ± 50.4537.9 ± 29.19—
Cycle 4 Day 1:Predose50.7 ± 52.1656.0 ± 61.5665.8 ± 115.3153.4 ± 81.6634.3 ± 54.9418.8 ± 34.3361.9 ± NA
Cycle 5 Day 1:Predose53.5 ± 56.6952.1 ± 65.1560.8 ± 58.3871.8 ± 134.3937.7 ± 42.9739.0 ± 29.50—
Cycle 6 Day 1:Predose40.6 ± 33.6651.8 ± 49.19114.0 ± 189.9749.9 ± 68.9736.9 ± 34.1234.2 ± 31.86—

Adverse events

Collected over From date of first dose of the study drugs up to 30 days after the last dose (up to 74 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCC1/2 (50%)1/2 (50%)2/2 (100%)
Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLC1/1 (100%)1/1 (100%)1/1 (100%)
Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: EC88/124 (71%)73/124 (58.9%)122/124 (98.4%)
Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCC74/145 (51%)81/145 (55.9%)145/145 (100%)
Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: Melanoma15/21 (71.4%)12/21 (57.1%)21/21 (100%)
Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLC16/21 (76.2%)15/21 (71.4%)21/21 (100%)
Phase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCC15/22 (68.2%)12/22 (54.5%)22/22 (100%)
Phase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UC16/20 (80%)17/20 (85%)20/20 (100%)
Phase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma1/1 (100%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 207
Most frequent serious events
EventPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
EncephalopathyNervous system disorders0/21/13/1241/1450/210/210/220/200/1
Clostridial sepsisInfections and infestations1/20/10/1240/1450/210/210/220/200/1
SepsisInfections and infestations0/20/11/1243/1450/210/210/223/200/1
AstheniaGeneral disorders0/20/12/1241/1451/210/210/222/200/1
PneumoniaInfections and infestations0/20/11/1246/1450/211/211/222/200/1
Acute kidney injuryRenal and urinary disorders0/20/11/1246/1450/210/211/222/200/1
DiarrhoeaGastrointestinal disorders0/20/12/1243/1450/212/210/220/200/1
CholecystitisHepatobiliary disorders0/20/10/1243/1452/210/210/220/200/1
SeizureNervous system disorders0/20/11/1240/1452/210/210/220/200/1
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/20/10/1240/1450/212/211/220/200/1
Most frequent other events
Showing 10 of 162
Most frequent other events
EventPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: Leiomyosarcoma
HypothyroidismEndocrine disorders1/21/161/12460/1457/218/216/228/200/1
DiarrhoeaGastrointestinal disorders2/21/179/12497/14513/2112/218/2211/200/1
DyspepsiaGastrointestinal disorders0/21/112/12421/1453/211/210/222/200/1
NauseaGastrointestinal disorders2/20/166/12474/14513/2110/219/2212/200/1
StomatitisGastrointestinal disorders2/21/145/12463/1451/215/217/222/201/1
VomitingGastrointestinal disorders1/20/156/12444/1459/218/216/2210/201/1
FatigueGeneral disorders2/21/166/12495/14514/2115/2111/2212/201/1
Skin infectionInfections and infestations2/20/10/1240/1450/210/210/220/200/1
Urinary tract infectionInfections and infestations0/21/137/1248/1456/213/212/229/200/1
Decreased appetiteMetabolism and nutrition disorders2/21/168/12470/14510/2116/2110/2210/200/1

Baseline characteristics

The safety analysis set included all participants who received at least one dose of study drug.

Age, Customized
Age, Customized(Participants)Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: LeiomyosarcomaTotal
<65 years004788169941174
>=65 years21775751213160183
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: LeiomyosarcomaTotal
Female0112432410461182
Male200113171118140175
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: LeiomyosarcomaTotal
Hispanic or Latino103172012026
Not Hispanic or Latino11121128192121181331
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: RCCPhase 1b, Lenvatinib 24 mg/Day + Pembrolizumab 200 mg: NSCLCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: ECPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: RCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: MelanomaPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: NSCLCPhase 1b and 2,Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: HNSCCPhase 1b and 2, Lenvatinib 20 mg/Day+Pembrolizumab 200 mg: UCPhase1b and 2, Lenvatinib 20mg/Day+Pembrolizumab 200 mg: LeiomyosarcomaTotal
American Indian or Alaska Native0010000001
Asian0053000008
Native Hawaiian or Other Pacific Islander0010000001
Black or African American00760320119
White21108125191820190312
More than one race00281001012
Unknown or Not Reported0003100004
08

Study locations

64 sites
  • Alaska Clinical Research Center
    Anchorage, Alaska, United States
  • Arizona Oncology Associates
    Oro Valley, Arizona, United States
  • Arizona Oncology Associates, PC - HOPE, Site #1
    Tucson, Arizona, United States
  • Arizona Oncology Associates, PC - HOPE, Site #2
    Tucson, Arizona, United States
  • Arizona Oncology Associates, PC - HOPE, Site #3
    Tucson, Arizona, United States
  • Rocky Mountain Cancer Centers
    Aurora, Colorado, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado, United States
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado, United States
  • Rocky Mountain Cancer Centers, Site #1
    Denver, Colorado, United States
  • Rocky Mountain Cancer Centers, Site #2
    Denver, Colorado, United States
  • Rocky Mountain Cancer Centers
    Lakewood, Colorado, United States
  • Rocky Mountain Cancer Centers
    Littleton, Colorado, United States
  • Rocky Mountain Cancer Centers
    Lone Tree, Colorado, United States
  • Rocky Mountain Cancer Centers
    Longmont, Colorado, United States
  • Rocky Mountain Cancer Centers
    Parker, Colorado, United States
  • Rocky Mountain Cancer Centers
    Pueblo, Colorado, United States
  • Rocky Mountain Cancer Centers
    Thornton, Colorado, United States
  • Baptist Health Medical Group Oncology, LLC, Site #1
    Miami, Florida, United States
  • Baptist Health Medical Group Oncology, LLC, Site #2
    Miami, Florida, United States
  • Baptist Health Medical Group Oncology, LLC, Site #3
    Miami, Florida, United States
  • Boca Raton Clinical Research Medical Center
    Plantation, Florida, United States
  • Piedmont Cancer Institue
    Atlanta, Georgia, United States
  • The University of Chicago
    Chicago, Illinois, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States
  • Mass General Hospital
    Boston, Massachusetts, United States
  • University of Minnesota, Masonic Cancer Center
    Minneapolis, Minnesota, United States
  • Comprehensive Cancer Centers of Nevada, Site #1
    Henderson, Nevada, United States
  • Comprehensive Cancer Centers of Nevada, Site #2
    Henderson, Nevada, United States
  • Comprehensive Cancer Centers of Nevada, Site #3
    Henderson, Nevada, United States
  • Comprehensive Cancer Centers of Nevada, Site #1
    Las Vegas, Nevada, United States
  • Comprehensive Cancer Centers of Nevada, Site #2
    Las Vegas, Nevada, United States
  • Comprehensive Cancer Centers of Nevada, Site #3
    Las Vegas, Nevada, United States
  • Comprehensive Cancer Centers of Nevada, Site #4
    Las Vegas, Nevada, United States
  • New York Hematology Oncology (US Onc)
    Albany, New York, United States
  • Memorial Sloan Kettering at Westchester
    Harrison, New York, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Oregon Health & Science University
    Portland, Oregon, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
  • Texas Oncology-Bedford
    Bedford, Texas, United States
  • Texas Oncology (US Onc)
    Dallas, Texas, United States
  • Texas Oncology
    Dallas, Texas, United States
  • Texas Oncology-Denton South
    Denton, Texas, United States
  • Texas Oncology-Fort Worth, Site #1
    Fort Worth, Texas, United States
  • Texas Oncology-Grapevine
    Grapevine, Texas, United States
  • Texas Oncology-Longview Cancer Center
    Longview, Texas, United States
  • Texas Oncology-Plano West
    Plano, Texas, United States
  • South Texas Accelerated Research Therapeutics, LLC
    San Antonio, Texas, United States
  • Texas Oncology-Tyler
    Tyler, Texas, United States
  • Texas Oncology-Waco, Site #1
    Waco, Texas, United States
  • Texas Oncology-Waco, Site #2
    Waco, Texas, United States
  • Haukeland Univerity Hospital
    Bergen, Norway
  • Sørlandet Hospital
    Kristiansand, 4604, Norway
  • Akershus Universitetssykehus HF
    Lørenskog, Norway
  • Oslo Univerity Hospital
    Oslo, Norway
  • Sykehuset Østfold
    Sarpsborg, Norway
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario De Fuenlabrada
    Fuenlabrada, Spain
  • Hospital La Paz
    Madrid, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, Spain
  • MD Anderson Cancer Center Madrid - España
    Madrid, Spain
  • Parc Taulí Sabadell
    Sabadell, Spain
  • Hospital Virgen de la Salud
    Toledo, Spain
  • Hospital Universitari i Politécnic La Fe.
    Valencia, Spain
09

References and documents

Publications

  • Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennoe OK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15. PubMed 34143969 ↗
  • Lee CH, DiNatale RG, Chowell D, Krishna C, Makarov V, Valero C, Vuong L, Lee M, Weiss K, Hoen D, Morris L, Reznik E, Murray S, Kotecha R, Voss MH, Carlo MI, Feldman D, Sachdev P, Adachi Y, Minoshima Y, Matsui J, Funahashi Y, Nomoto K, Hakimi AA, Motzer RJ, Chan TA. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. Mol Cancer Res. 2021 Sep;19(9):1510-1521. doi: 10.1158/1541-7786.MCR-21-0053. Epub 2021 May 26. PubMed 34039647 ↗
  • Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. PubMed 32167863 ↗
  • Taylor MH, Lee CH, Makker V, Rasco D, Dutcus CE, Wu J, Stepan DE, Shumaker RC, Motzer RJ. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020 Apr 10;38(11):1154-1163. doi: 10.1200/JCO.19.01598. Epub 2020 Jan 21. Erratum In: J Clin Oncol. 2020 Aug 10;38(23):2702. doi: 10.1200/JCO.20.01942. PubMed 31961766 ↗
  • Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25. PubMed 30922731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Aug 2020, 60 months.

Results were first posted in Jul 2023, 2 years 11 months after primary completion. A results delay was requested in Jun 2021.

Of 194 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 60 months is close to that.

Counting every sponsor, half of 296 studies reached it within 60 months; a quarter within 39 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2015
First posted
Jul 17, 2015
StartActual
Jul 22, 2015
Primary completionActual
Aug 18, 2020
CompletionActual
Jul 11, 2022
Results delay requested
Jun 11, 2021
Results first posted
Jul 20, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02501096
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jul 17, 2015
Start date
Jul 22, 2015
Primary completion
Aug 18, 2020
Completion
Jul 11, 2022
Results posted
Jul 20, 2023
Last update
Jul 20, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion